long intergenic non-protein coding RNA 2189Genealiases: []
Q-omics provides the consensus-scored LINC02189 profile across patient tissues and cancer cell-line models. LINC02189 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02189 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, LINC02189 RNA expression shows 7,672 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, BRCA, and CCRCC as cancer lineages where LINC02189 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02189 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02189 survival associations across molecular data types. LINC02189 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02189 RNA expression–survival associations across cancer types. High LINC02189 expression shows unfavorable associations in UCS, BLCA, MESO, LUAD and COAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02189 RNA expression.
This table summarizes LINC02189 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02189. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02189 shows lower tumor expression in BRCA. The BRCA box plot shows higher LINC02189 RNA expression in normal versus tumor tissue (log2 FC = −0.233, t-test p = .003).
This table shows molecular features associated with LINC02189 in patient tissues and cancer cell lines. In patient samples, LINC02189 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
